CLINICAL CHARACTERISTICS FROM A REAL-WORLD POPULATION OF NASH PATIENTS- FINDINGS FROM THE GAIN (GLOBAL ASSESSMENT OF THE IMPACT OF NASH) SOCIOECONOMIC STUDY
Author(s)
Rose A1, Russell T2, Ruiz L2, O'Hara J2, Morgan G2, Franks B2
1HCD Economics, Warrington, UK, 2HCD Economics, Daresbury, UK
OBJECTIVES NASH is a growing chronic liver condition associated with significant humanistic burden. Despite this, there is little information available on the NASH burden from a societal perspective. The aim of the GAIN-Study is to determine the socio-economic burden of NASH in adult patients in Europe (France, Spain, Italy, Germany and the United Kingdom) and the United States in a real-world setting. METHODS Data were drawn from the “Global Assessment of the Impact of NASH: a socioeconomic study” (GAIN), a retrospective prevalence-based and bottom up burden of disease study of patients with NASH. This study follows a retrospective and cross-sectional methodology that recruits a sample of physicians and provides demographic, clinical and economic information, including 12-month ambulatory and secondary care activity for patients via an online survey. Physicians complete a Patient Record Form (PRF) for the next 10 eligible patients and invite each patient to complete a corresponding patient self-completion questionnaire at a singular point in time. RESULTS 337 physicians provided information on 3,754 patients of which 57% were male, with a mean age of 53.4 (11.9). Patients diagnosed by liver biopsy (n=1,619) were stratified by fibrosis score (F0-F4). Patients diagnosed by serum biomarkers and imaging techniques (n=2,135) were stratified with early (F0-F2) or advanced (F3-F4) fibrosis. Obesity, dyslipidaemia, hypertension and diabetes were present in 1,320 (35%), 1,199 (32%), 1,027 (27%) and 997 (27%) of patients respectively. 267 (7%) of patients were hospitalised at least once in the 12 months prior to the date of clinical consultation, for reasons related and unrelated to their NASH condition and increased with the presence of comorbidities. CONCLUSIONS Results show patients at various stages of liver impairment with a high number of comorbidities, which will likely contribute to the economic, clinical and humanistic burden of this disease. As expected, the hospitalisation rates are correlated with presence of comorbidities.
Conference/Value in Health Info
2019-05, ISPOR 2019, New Orleans, LA, USA
Value in Health, Volume 22, Issue S1 (2019 May)
Code
PDB123
Topic
Economic Evaluation, Methodological & Statistical Research, Patient-Centered Research
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies, Patient-reported Outcomes & Quality of Life Outcomes, PRO & Related Methods
Disease
Diabetes/Endocrine/Metabolic Disorders